Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR… GlobalNewsWire May 6, 2024 Phase 1 trial shows 90 per cent recurrence-free survival and 90 per cent complete response in patients with high-risk and…
Amgen says Lumakras cuts risk of lung cancer progression by 34 per cent Reuters Sep 12, 2022 The medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13 per cent of non-small cell…
